Jazz Pharmaceuticals $1.5 billion acquisition of Celator Pharmaceuticals

Overview:

• Jazz Pharmaceuticals has acquired Celator Pharmaceuticals in a $1.5 billion deal.
• The purchase gives Jazz access to Celator's Vyxeos leukemia treatment.
• Jazz was previously based in California before acquiring an Irish pharmaceutical company in 2012.
• Cooley advised the acquirer.
• Kirkland & Ellis advised Celator.

Kurt Stumpo - Journalist - North America and the Caribbean